Studies of Propionate Toxicity in Salmonella enterica Identify 2-Methylcitrate as a Potent Inhibitor of Cell Growth*

Alexander R. HorswillDagger, Andrea R. Dudding, and Jorge C. Escalante-Semerena§

From the Department of Bacteriology, University of Wisconsin, Madison, Wisconsin 53706-1567

Received for publication, January 10, 2001, and in revised form, March 16, 2001


    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Salmonella enterica serovar Typhimurium LT2 showed increased sensitivity to propionate when the 2-methylcitric acid cycle was blocked. A derivative of a prpC mutant (which lacked 2-methylcitrate synthase activity) resistant to propionate was isolated, and the mutation responsible for the newly acquired resistance to propionate was mapped to the citrate synthase (gltA) gene. These results suggested that citrate synthase activity was the source of the increased sensitivity to propionate observed in the absence of the 2-methylcitric acid cycle. DNA sequencing of the wild-type and mutant gltA alleles revealed that the ATG start codon of the wild-type gene was converted to the rare GTG start codon in the revertant strain. This result suggested that lower levels of this enzyme were present in the mutant. Consistent with this change, cell-free extracts of the propionate-resistant strain contained 12-fold less citrate synthase activity. This was interpreted to mean that, in the wild-type strain, high levels of citrate synthase activity were the source of a toxic metabolite. In vitro experiments performed with homogeneous citrate synthase enzyme indicated that this enzyme was capable of synthesizing 2-methylcitrate from propionyl-CoA and oxaloacetate. This result lent further support to the in vivo data, which suggested that citrate synthase was the source of a toxic metabolite.


    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Short chain fatty acids (SCFAs)1 are common by-products of bacterial fermentations and are produced in abundance in the gastrointestinal tracts of mammals (1). Although SCFAs are a good source of carbon and energy for procaryotes, they also are a hazard because they inhibit cell growth (2). The growth inhibitory properties of SCFAs have made them useful as preservatives in the food industry (2, 3). Propionate (a three-carbon SCFA) is one of the most abundant fermentation by-products, and it is extensively used in the food industry to protect baked goods against microbial contamination (4).

Enteric bacteria such as Salmonella spp. are exposed to high concentrations of propionate in their environments. In the gastrointestinal tract of humans, fermentative bacteria such as Bacteriodes and Veillonella can produce propionate levels as high as 23.1 mmol/kg (1, 5-7). In the cecum of chickens and mice, propionate can reach levels of 9.7 and 4.4 mmol/kg, respectively (8, 9). Salmonella spp. may also encounter propionate in many food products such as baked goods and cheese where concentrations range from 10 to 50 mM (3, 4).

Studies on propionate and other SCFAs have shown they are major determinants in the ability of Salmonella spp. to cause disease. SCFAs produced by fermentative bacteria in mice and chickens can greatly increase resistance to Salmonella infections (8, 10-12). These properties have prompted researchers to test the ability of propionate to inhibit Salmonella growth in animal feeds. The addition of propionic acid to chicken feeds at levels of 60-100 mM greatly reduced the population of Salmonella spp. and limited the ability of Salmonella to colonize the chicken cecum (6, 13-15).

Our understanding of the mechanisms through which propionate exerts antimicrobial activity is limited. This compound appears to affect the function of multiple targets within the cell. For example, SCFAs are known to dissipate the proton-motive force of cell membranes by entering the cell as undissociated molecules and then dissociating in the cytoplasm (3, 16, 17). Other lines of evidence suggest that the intracellular accumulation of the SCFA anions blocks metabolic pathways, arresting cell growth (18). Reports in the literature suggest that propionyl-coenzyme A (propionyl-CoA) is an important contributor to the observed toxicity of propionate. In Rhodobacter sphaeroides, propionyl-CoA was found to inhibit pyruvate dehydrogenase (19), and in Escherichia coli, propionyl-CoA is a competitive inhibitor of citrate synthase (20). Support for the idea that propionyl-CoA is a problem for the cell was also obtained in Aspergillus niger, where experiments blocking propionyl-CoA formation relieved propionate sensitivity (21). However, recent experiments suggest that the inhibitory effects of propionate in A. niger may be caused by 2-methylcitrate accumulation (22).

The ability of microorganisms to metabolize SCFAs may be the primary line of defense against the negative effects of these compounds on cell growth (2, 4). Enteric bacteria such as Salmonella enterica serovar Typhimurium LT2 and E. coli catabolize propionate via the 2-methylcitric acid cycle (23, 24). However, when this pathway was blocked in Salmonella, sensitivity to propionate increased dramatically (25), suggesting that intermediates of the 2-methylcitric acid cycle may have a more profound negative effect on cell growth than propionate itself. This idea would be consistent with reports in the literature where D-threo-alpha -methylisocitrate was found to inhibit bovine heart NADP isocitrate dehydrogenase (26) and synthetic 2-methylcitrate was found to inhibit aconitase and citrate synthase activities (27).

This paper reports the isolation and characterization of a derivative of a prpC mutant (lacks methylcitrate synthase activity) of S. enterica serovar Typhimurium LT2 with increased resistance to propionate. The data indicate that by lowering the level of citrate synthase in the prpC mutant, the negative effect of propionate was drastically relieved. The data strongly suggest that 2-methylcitrate is a toxic catabolite or the precursor of an as yet unidentified toxic compound.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Culture Media and Growth Conditions

Nutrient broth (NB) at 0.8% (w/v) containing 85 mM NaCl (28) was routinely used as rich medium. E. coli cultures were maintained in Luria-Bertani (LB) broth. No-carbon E medium supplemented with 1 mM MgSO4 and 0.5 mM methionine was used as a minimal medium (28, 29). The final concentrations of compounds provided in culture medium were as follows: 50 mM acetate, 20 mM citrate, 11 mM glucose, 5 mM glutamate, 30 mM glycerol, 30 mM malate, 30 mM propionate, and 50 mM succinate. Antibiotic concentrations in rich medium were 100 µg/ml ampicillin, 50 µg/ml kanamycin, and 20 µ g/ml tetracycline. Antibiotic concentrations for plasmids in minimal medium were 50 µg/ml ampicillin and 50 µg/ml kanamycin. All chemicals were purchased from Sigma unless otherwise stated. A list of strains and plasmids used and their genotypes is provided in Table I.

Growth Curves

Overnight cultures of strains grown in NB were subcultured 1:100 (v/v) in duplicate into 5 ml of minimal medium with appropriate supplements. Cultures were incubated in 18 × 150-mm tubes at 37 °C with shaking, and cell growth was monitored at 650 nm with a Spectronic 20D spectrophotometer furnished with a red filter (Milton Roy Co., Rochester, NY).

Genetic Crosses

Transductions involving phage P22 HT105 int-201 (30, 31) were performed as described (28). Transductants were freed of phage as described (32).

Recombinant DNA Techniques

Restriction and modification enzymes were purchased from Promega Corp. (Madison, WI) unless otherwise stated and were used according to the manufacturer's instructions. All DNA manipulations were performed in E. coli DH5alpha /F'. Plasmids were transformed into E. coli or S. enterica serovar Typhimurium LT2 by CaCl2 heat shock as described (33). Plasmids transferred into Salmonella were first transformed into recombination-deficient or S. enterica serovar Typhimurium LT2 strain JR501 (34). Plasmids from strain JR501 were transformed into other Salmonella strains as described (35).

Isolation of Strains Resistant to Propionate

Ten tubes containing 2 ml of NB broth each were inoculated with isolated colonies of strain JE2170 (prpC114::MudJ) and grown overnight at 37 °C with shaking. Cells in a 1-ml sample from each culture were pelleted in 1.5-ml microcentrifuge tubes for 2 min at 15,000 × g in a MarathonTM 16KM microcentrifuge (Fisher). The spent medium supernatant was removed, and cells were resuspended in 100 µl of sterile saline and plated on minimal medium supplemented with succinate, propionate, and kanamycin. After 4 days of incubation at 37 °C, revertants were observed. These colonies were picked and streaked for isolation on the same medium. One revertant in particular grew better than the others and was selected for further characterization. A phage P22 lysate was prepared on this strain and used to transduce strain JE2170 to growth on succinate in the presence of propionate. The reconstructed strain was freed of phage and saved as strain JE3777. As shown below, the mutation responsible for the observed resistance to propionate toxicity in this strain changes the start codon of the gltA gene from ATG (Met) to GTG (Met). Because the mutation did not change the amino acid sequence of the GltA protein, the mutant allele is hereafter referred to as gltAGTG.

Mapping the gltAGTG Mutation

Unlike its parent strain, strain JE3777 (prpC114::MudJ gltAGTG) failed to utilize acetate as carbon and energy source. This growth phenotype was used to isolate a Tn10DEL16DEL17 element (hereafter referred to as Tn10d(Tc)) near gltAGTG. Briefly, phage P22 was grown on a pool of strains (approximately 100,000) each assumed to contain one transposition-defective Tn10d(Tc) element (36), and a P22 lysate was prepared. This lysate was used to transduce strain JE3777 to tetracycline resistance. Tetracycline-resistant (Tcr) transductants that regained the ability to grow on acetate were freed of phage and analyzed further. A Tn10d(Tc) element close to gltAGTG (>90% cotransducible by P22) was isolated, moved back into strain JE3777, and saved as strain JE3845 (prpC114::MudJ gltAGTG zbg-6391::Tn10d(Tc)).

Determination of DNA Sequence Flanking the zbg-6391::Tn10d(Tc) Element

Arbitrary primer PCR was used to identify a DNA sequence flanking the linked insertion (37, 38). Chromosomal DNA of strain JE3845 was prepared using the MasterPureTM genomic DNA isolation kit (Epicentre, Madison, WI). Two 50-µl reactions were prepared for the first round of PCR using 1 µg of DNA template, 50 pmol of each primer, 0.2 mM of each dNTP (Promega), and Vent® Exo- DNA polymerase (New England Biolabs, Beverly, MA) in a GeneAmp® PCR System 2400 (PerkinElmer Life Sciences). Primers used were as follows: Tn10-L, 5'-TCCATTGCTGTTGACAAA-3'; Tn10-R, 5'-ACCTTTGGTCACCAACGCTT-3'; and ARB1, 5'-GGCCACGCGTCGACTAGTACNNNNNNNNNNGATAT-3'. The first PCR round used the following conditions: 5 cycles at 94 °C for 30 s, 30 °C for 30 s, and 72 °C for 2 min and then 30 cycles at 94 °C for 30 s, 45 °C for 30 s, and 72 °C for 2 min. In the second round of PCR, amplified DNA from the first round reactions was used to enrich for DNA flanking the Tn10d(Tc) element. Two 50-µl reactions were prepared as described above substituting 1 µl of DNA obtained during PCR round 1 for chromosomal DNA template. Primers used were as follows: Tn10-I, 5'-GACAAGATGTGTATCCAC-3'; and ARB2, 5'-GGCCACGCGTCGACTAGTAC-3'. The second round of PCR used the following conditions: 30 cycles at 94 °C for 30 s, 55 °C for 30 s, and 72 °C for 1 min. PCR amplification was verified by agarose gel electrophoresis (39) using 2% gels. Amplified DNA was purified using the QIAquick® PCR purification kit (Qiagen, Chatsworth, CA). PCR sequencing reactions were prepared using the ABI PRISM® dye terminator cycle sequencing kit (PerkinElmer Life Sciences) according to the manufacturer's instructions. Reactions were purified in AutoSeq® G-50 columns (Amersham Pharmacia Biotech), dried in a SpeedVac® concentrator (Savant Instruments, Farmingdale, NY), and sequenced at the Biotechnology Center of the University of Wisconsin, Madison.

Sequencing of the gltA Gene and the gltAGTG Mutation

A primer for the 3' end of the gltA gene (5'-CGGAAGGTCTAGATAGAGAAAAATA-3') was designed from the sequence obtained using the Tn10-L side of the zbg-6391::Tn10d(Tc) element in JE3845 (see above). A primer for the 5' end of gltA (5'-GATCCAGATCTAGAGGTCTTTGTTT-3') was designed based on the reported sequence (40). The gltA gene was sequenced in its entirety by PCR amplifying the gene from strain TR6583 (gltA+) and directly sequencing the entire PCR fragment by primer walking. DNA template for the PCR reactions was prepared by mixing 10 µl of NB overnight cultures of strain TR6583 with 90 µl of water, heating the cell suspensions to 100 °C for 5 min, and centrifuging them for 1 min at 15,000 × g in a Marathon 16KM microcentrifuge (Fisher). PCR reactions were prepared using one-tenth the volume of boiled template, 50 pmol of each primer, 0.2 mM of each dNTP, and Pfu polymerase (Stratagene, La Jolla, CA) according to the manufacturer's instructions. Reactions were performed using the following conditions: 30 cycles at 94 °C for 90 s, 50 °C for 30 s, and 72 °C for 90 s. The PCR reactions were verified and purified, and the DNA was sequenced as described above. Sequences of all of the primers used for primer walking can be provided upon request. Each side of the gltA gene was sequenced at least two times. The DNA sequence was compiled and submitted to GenBankTM (accession number AF056043). The gltAGTG mutation in JE3777 was identified by sequencing the entire gltA gene.

Plasmid Constructions

Plasmid pPRP68-- The prpE gene was PCR-amplified as described above using an NdeI primer for the 5' end (5'-CAGGAGAGCCATATGTCTTTTAGC-3') and a 3' end primer (5'-TTCTTCGATCGCCTGGC-3'). The PCR fragment was purified as described above, digested with NdeI, and cloned into pTYB2 (New England Biolabs, Beverly, MA) cut with the same enzyme. The resulting plasmid was named pPRP68 (9.4 kb, Apr). PrpE protein purified using this plasmid has an additional C-terminal glycine residue.

Plasmid pGLTA1-- The gltA gene was PCR-amplified as described above (using same primers) and cloned to make plasmid pGLTA1 (4.3 kb, Apr). The PCR fragment was cloned by A-tailing the DNA and ligating into pGEM®-T cloning vector using the pGEM®-T vector system kit (Promega) according to the manufacturer's instructions.

Plasmid pGLTA2-- Plasmid pGLTA1 was digested with enzymes KpnI and XbaI (sites in primers) to remove the gltA gene as a 1.3-kb fragment. This piece was cloned into plasmid pBAD30 (41) cut with the same enzymes to generate plasmid pGLTA2 (6.2 kb, Apr).

Plasmid pGLTA3-- The gltA gene was PCR-amplified as described above using a NdeI primer for the 5' end (5'-GAGACCGCATATGGCTGATACA-3') and a BamHI primer for the 3' end (5'-CATCCGGATCCCAATTAACG-3'). The PCR fragment was purified using the QIAquick® PCR purification kit (Qiagen), digested with NdeI and BamHI, and cloned into pET-15b (Novagen, Madison, WI) cut with the same enzymes. The resulting plasmid was named pGLTA3 (7 kb, Apr). The GltA protein encoded by plasmid pGLTA3 contained a hexahistidine tag at its N terminus (H6GltA).

Purification of the Propionyl-CoA Synthetase (PrpE) Enzyme

Overexpression of prpE-- Plasmid pPRP68 (encodes PrpE) was transformed into E. coli ER2566, and the resulting strain, JE4813, was used to overexpress and purify PrpE protein. To overexpress prpE, 20 ml of an LB overnight culture of JE4813 was used to inoculate 1 liter of SOC broth (42, 43) containing ampicillin. The culture was grown at 20 °C with shaking to an absorbance of 0.3 at 600 nm. Isopropyl-beta -D-thiogalactopyranoside was added to a final concentration of 0.5 mM, and the culture was incubated for 18 h with shaking at 20 °C. Cells were pelleted in 250-ml bottles by centrifugation for 10 min at 10,500 × g at 4 °C using a GSA rotor (DuPont). Cell pellets were stored at 4 °C no longer than 16 h before use.

Purification of PrpE-- Cells overexpressing PrpE were resuspended in 100 ml of 20 mM HEPES, pH 7.5, containing 0.5 M KCl, 1.0 mM EDTA, and 0.1% Triton X-100. Cells were centrifuged in 250-ml bottles as described above and resuspended in 20 ml of the same buffer. Cells were broken by French press at 1.03 × 107 kPa using a chilled pressure cell. Cell debris was removed by centrifugation in 50-ml Oakridge tubes at 31,000 × g for 30 min at 4 °C using a SS34 rotor (DuPont). PrpE protein was purified on chitin beads (New England Biolabs) according to the manufacturer's instructions. Following purification, the enzyme was dialyzed at 4 °C against 1 liter of 50 mM HEPES buffer, pH 7.5, containing 1 mM EDTA, 100 mM KCl, and 0.25 mM Tris(2-carboxyethyl)phosphine hydrochloride. The dialysis buffer was replaced after 2 h and again after 4 h (20% glycerol (v/v) added to the buffer). The PrpE protein was dialyzed overnight and stored at -80 °C in this buffer.

Propionyl-CoA Synthetase Assays-- The propionyl-CoA synthetase activity was monitored using a myokinase, pyruvate kinase, and lactate dehydrogenase coupling assay (44). Standard assays (0.8 ml of reaction mixture volume) contained 50 mM HEPES buffer, pH 7.5, 0.1 M KCl, 5% glycerol (v/v), 3.0 mM phosphoenolpyruvate, 1.0 mM propionate, 0.25 mM NADH, 0.2 mM CoA, 0.4 mM ATP, 1.0 mM MgCl2, 15 units of myokinase, 13 units of pyuvate kinase, and 25 units of lactate dehydrogenase. For these assays, buffer and substrates were preincubated in quartz cuvettes at 37 °C in a Lambda 6 spectrophotometer (PerkinElmer Life Sciences) equipped with a water-jacketed cuvette holder. After 5 min, assays were started by the addition of PrpE enzyme, and the reaction was monitored for 10 min at 340 nm. Specific activities were calculated from the extinction coefficient (12,440 M-1 cm-1) of the oxidation of two molecules of NADH per AMP released. Specific activity was reported as micromoles of AMP generated per min per mg of protein.

Biochemical Characterization of the Citrate Synthase (GltA) Enzyme

Preparation of Cell-free Extracts-- Five ml of NB overnight cultures of strains TR6583, JE2170, and JE3777 were subcultured into 500 ml of minimal medium supplemented with succinate and glutamate. The cultures were grown at 37 °C with shaking for 24 h. Cells were pelleted in 250 ml of Nalgene® polypropylene copolymer bottles (Fisher) by centrifugation for 10 min at 10,500 × g at 4 °C using a GSA rotor in a RC-5B refrigerated centrifuge (DuPont). Cells were resuspended in 100 ml of 50 mM HEPES, pH 7.5, containing 100 mM KCl, 1 mM EDTA, and 0.2 mM of the protease inhibitor phenylmethanesulfonyl fluoride. Cells were centrifuged in 250-ml bottles as described above and resuspended in 5 ml of the same buffer. Cell suspensions were kept on ice and broken by sonication (10 min, 50% duty, setting 3) with a model 550 Sonic Dismembrator (Fisher). Cell debris was removed by centrifugation in 50-ml Nalgene® polypropylene copolymer Oakridge tubes (Fisher) at 31,000 × g for 30 min at 4 °C with a SS34 rotor (DuPont). Supernatants were dialyzed at 4 °C in SnakeSkin® 10,000 molecular weight cut off dialysis membrane (Pierce) against 1 liter of 50 mM HEPES, pH 7.5, containing 100 mM KCl, 1 mM EDTA, and 0.2 mM phenylmethanesulfonyl fluoride. The dialysis buffer was replaced after 2 and 4 h and then allowed to dialyze an additional 16 h. Dialyzed cell-free extracts were tested for citrate synthase activity as described below.

Overexpression of gltA-- Plasmid pGLTA3 (encodes H6GltA) was transformed into E. coli ER2566, and the resulting strain, JE4905, was used to overexpress and purify H6GltA protein. To overexpress gltA, 20 ml of an LB overnight culture of JE4905 was used to inoculate 2 liters of LB broth containing ampicillin. The culture was grown at 37 °C with shaking to an absorbance of 0.5 at 600 nm. Isopropyl-beta -D-thiogalactopyranoside was added to a final concentration of 0.3 mM, and the culture was incubated for 4.5 h with shaking at 37 °C. Cells were pelleted in 250-ml bottles by centrifugation for 10 min at 10,500 × g at 4 °C using a GSA rotor (DuPont). Cell pellets were stored at 4 °C no longer than 16 h before use.

Purification of the GltA Protein-- Cells overexpressing H6GltA were resuspended in 100 ml of 50 mM HEPES, pH 7.5, containing 100 mM KCl and 0.2 mM phenylmethanesulfonyl fluoride. Cells were centrifuged in 250-ml bottles as described above, and cells were resuspended in 20 ml of the same buffer. Cell were broken by a French press at 1.03 × 107 kPa using a chilled pressure cell. Cell debris was removed by centrifugation in 50-ml Oakridge tubes at 31,000 × g for 30 min at 4 °C using a SS34 rotor (DuPont). H6GltA protein was purified on His·BindTM resin (Novagen) according to the manufacturer's instructions. Following purification, the enzyme was dialyzed at 4 °C against 1 liter of 50 mM HEPES buffer, pH 7.5, containing 5 mM EDTA and 100 mM KCl. The dialysis buffer was replaced after 2 h (EDTA lowered to 1 mM) and again after 4 h (5% glycerol (v/v) added to the buffer). The H6GltA protein was dialyzed overnight and stored at -80 °C in this buffer

Citrate Synthase Activity Assays

Citrate synthase activity was monitored spectrophotometrically as described (45). Standard citrate synthase assays (0.8 ml of reaction mixture volume) contained 50 mM HEPES buffer, pH 7.5, 0.1 M KCl, 5% glycerol (v/v), 0.2 mM 5,5'-dithiobis-(2-nitrobenzoic acid), 0.1 mM oxaloacetate, and 0.1 mM acetyl-CoA. To assay for 2-methylcitrate synthase activity, the same conditions were used except propionyl-CoA was substituted for acetyl-CoA. For these assays, buffer and substrates were preincubated in 1.5-ml methacrylate cuvettes (Fisher) at 37 °C in a Lambda 6 spectrophotometer (PerkinElmer Life Sciences) equipped with a water-jacketed cuvette holder. After 5 min, assays were started by the addition of H6GltA enzyme, and the reaction was monitored for 10 min at 412 nm. Specific activities were calculated from the extinction coefficient (13,600 M-1 cm-1) of the thionitrobenzoate dianion (46). The specific activity was reported as nanomoles of thionitrobenzoate dianion generated per min per mg of protein.

Detection of [C-2,14C]2-Methylcitrate

H6GltA-dependent 2-methylcitrate synthesis was tested using [C-2,14C]propionyl-CoA. [C-2,14C]Propionyl-CoA was synthesized from [C-2,14C]propionate (55 µCi/mmol; Moravek Biochemicals, Brea, CA) using PrpE, the propionyl-CoA synthetase (47). The PrpE reaction mixture contained: [C-2,14C]propionate, (0.02 µmol), ATP, (0.12 µmol), MgSO4 (0.3 µmol) in 50 mM HEPES buffer, pH 7.5, containing 100 mM KCl, 5% glycerol (v/v), and 2 µg of PrpE protein (prepared as described in Ref. 47). The final volume was 100 µl. This reaction mixture was incubated for 1 h at 37 °C. The PrpE reaction was divided into three 33-µl samples. Oxaloacetate (0.05 µmol) was added to two of these samples, and 2-methylcitrate was synthesized upon the addition of 1.2 µg of PrpC (2-methylcitrate synthase prepared as described) (23) or 7.5 µg of GltA. The third sample was used as a no-addition control. The three reactions were incubated at 37 °C for 3 h. Five-µl samples were removed after 1 and 3 h of incubation. The samples were diluted 4-fold with reaction buffer containing 3 M HCl. Five µl of the acid-treated samples was spotted onto a silica gel TLC plate with fluorescence (Whatman Ltd., Maidstone, Kent, UK) and air-dried for 30 min. The TLC plate was developed with a chloroform:methanol (3:2) mobile phase for about 30 min. The plates were dried in a flow hood for 1 h before exposing the TLC plate overnight to a PhosphorImager screen (Molecular Dynamics, Sunnyvale, CA).

Inhibition of Aconitase A (AcnA) and Aconitase B (AcnB)

Overexpression and Purification-- The acnA and acnB genes were overexpressed, and the AcnA and AcnB proteins were purified as previously described.2

2-Methylcitrate Inhibition-- Aconitase activity was monitored as previously described.2 In inhibition studies, 2-methylcitrate was added to final concentrations ranging from 0.5 to 5.0 mM. Synthetic 2-methylcitrate was purchased from C/D/N Isotopes (Pointe-Claire, Quebec, Canada) as a mixture of four stereoisomers.

Other Procedures

Protein concentrations were determined by the method of Bradford (49) using the Bio-Rad protein reagent. A standard curve was generated for protein determinations with bovine serum albumin. Proteins were separated by SDS-polyacrylamide gel electrophoresis (50) using 12% polyacrylamide gels and were visualized with Coomassie Blue (51). Mid-range standards (14-97.4 kDa) were used for SDS-polyacrylamide gel electrophoresis (Promega). UV-visible spectroscopy was performed in a computer-controlled Lambda Bio-6 spectrophotometer (PerkinElmer Life Sciences).

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Isolation and Characterization of a Propionate-resistant Strain-- A derivative of strain JE2170 (prpC114::MudJ) with improved growth on succinate in the presence of propionate was isolated. The new strain (strain JE3777; Table I) showed a slower growth rate (8.0 h doubling-1) than the prpC+ (3.3 h doubling-1, strain TR6583) on minimal medium supplemented with succinate and propionate (Fig. 1B). In addition, strain JE3777 stayed in lag phase for ~30 h, a lag that was 10-fold longer than the one measured for strain TR6583. The effect of the mutation in strain JE3777 was not dependent on the use of succinate as a carbon and energy source. The same relief of propionate toxicity was observed when malate substituted for succinate. The mutation responsible for the propionate resistance of strain JE3777 did not improve the growth of this strain when citrate or glycerol substituted for succinate in the presence of propionate (data not shown).

                              
View this table:
[in this window]
[in a new window]
 
Table I
Strain and plasmid list


View larger version (15K):
[in this window]
[in a new window]
 
Fig. 1.   Growth curves of wild-type (TR6583, open circles), prpC214::MudJ mutant (JE2170, open squares), and gltAGTG revertant (JE3777, closed squares) on different carbon sources. A shows growth on 50 mM succinate, and B shows growth on 50 mM succinate with 30 mM propionate.

Further phenotypic characterization of strain JE3777 revealed that this strain was unable to grow on acetate as a carbon and energy source (data not shown). Genetic crosses established that the inability of strain JE3777 to grow on acetate correlated with the inheritance of the mutation responsible for the resistance to propionate, not with the presence of the insertion in prpC (data not shown). The acetate phenotype was used to isolate Tn10d(Tc) elements near the mutation, causing resistance to propionate. Comparisons of the nucleotide sequences of the regions flanking element zbg-6391::Tn10d(Tc) (90% cotransducible with the propionate resistance mutation) with those in the data bases located this element near the gltA gene (encodes citrate synthase). On the basis of these results, the mutation responsible for the resistance to propionate was postulated to be an allele of gltA. The known inability of gltA null mutants to grow on acetate supported this idea (52).

Resistance to Propionate Is Afforded by Lower Levels of Citrate Synthase (GltA) Enzyme-- To identify the nature of the mutation responsible for the newly acquired resistance to propionate of strain JE3777, the alleles of gltA in strains TR6583 (gltA+) and JE3777 (unknown gltA allele) were sequenced. In both cases, the gltA gene was amplified with a proofreading DNA polymerase, followed by sequencing of both strands by primer walking. The nucleotide sequence of the wild-type gltA gene from strain TR6583 was deposited into GenBankTM (accession number AF056043). Comparison of the wild-type gltA sequence with the one found in strain JE3777 revealed a single point mutation that converted the start methionine codon from ATG to GTG. Although GTG encodes for methionine, it is rarely used as the start codon in enteric bacteria (53), suggesting that strain JE3777 would make low levels of wild-type GltA protein because of the limited pools of the GTG-tRNA-Met. Hereafter, the allele in strain JE3777 is referred to as gltAGTG to distinguish it from mutations that alter the amino acid sequence of the wild-type GltA protein.

Consistent with the idea that strain JE3777 must contain low levels of citrate synthase activity, dialyzed, cell-free extracts of strain TR6583, strain JE3777, and strain JE3884 (gltA1182::MudJ, a null allele) were prepared, and GltA activity was measured. The specific activity of GltA in strain TR6583 was 155 nmol of product/min/mg of protein. The GltA activity in cell-free extracts of strain JE3777 was 12 nmol of product/min/mg of protein, a 12-fold reduction relative to the activity measured in strain TR6583 carrying the wild-type allele of gltA. As expected, no citrate synthase activity was detected in cell-free extracts of strain JE3884.

The isolation of a propionate-resistant strain with reduced citrate synthase levels suggested that, in the prpC gltA+ strain, wild-type levels of citrate synthase activity was a problem during growth on propionate, although it was not clear why. If this idea were correct, one would predict that strains lacking citrate synthase activity would be resistant to propionate, provided that the culture medium was supplemented with glutamate. To test this idea directly, a gltA null allele (i.e. gltA1182::MudJ) was introduced into a prpC mutant (JE3907), and growth of the resulting strain (JE4556) on succinate was shown to be unaffected by propionate (Fig. 2). The null allele of gltA was as effective at relieving propionate toxicity as was the gltAGTG allele, except that the gltAGTG allele did not cause a glutamate auxotrophy. Clearly, the low levels of citrate synthase activity present in strain JE3777 were sufficient to satisfy the glutamate requirement of the cell.


View larger version (123K):
[in this window]
[in a new window]
 
Fig. 2.   Plate phenotypes of wild-type prpBCDE+ (TR6583), prpC point mutant (JE3907), prpD point mutant (JE3947), gltAGTG revertant (JE3777), gltA1182::MudJ mutant (JE3884), prpC gltA double mutant (JE4556), and prpD gltA double mutant (JE4550). All four plates contain 50 mM succinate minimal medium with different supplements. A has no supplements, B is supplemented with 5 mM glutamate, C is supplemented with 30 mM propionate, and D is supplemented with 30 mM propionate and 5 mM glutamate. In all panels gltA* = gltAGTG.

These results suggested that GltA activity, not the absence of it, caused the toxic effect of propionate in the prpC point mutant (Fig. 2). It was not surprising that gltA null mutants were not isolated during our search for propionate-resistant strains because glutamate was not included in the culture medium.

Accumulation of 2-Methylcitrate Is Deleterious to Cell Growth-- It should be noted that the null allele of gltA (i.e. gltA1182::MudJ) failed to relieve the propionate toxicity when introduced into a prpD point mutant (strain JE3947). Growth of the gltA prpD double mutant strain (JE4550) was strongly inhibited by propionate in the medium (Fig. 2). It was concluded that the inhibitor of cell growth was 2-methylcitrate or a derivative of it, because prpD mutants are known to accumulate 2-methylcitrate when the medium is supplemented with propionate (23).

Correlation between High Levels of Citrate Synthase and Propionate Toxicity-- To establish a direct correlation between the level of GltA and the toxic effects of propionate, gltA was placed under the control of an inducible promoter. Plasmid pGLTA2 (ParaBAD-gltA+) was used for this purpose, because it carried the wild-type gltA+ allele under the control of the arabinose-inducible ParaBAD promoter (41). Plasmid pGLTA2 complemented the glutamate auxotrophy of strain JE3884 (gltA1182::MudJ) on minimal medium supplemented with glucose but lacking arabinose (data not shown). This suggested that residual levels of GltA enzyme were synthesized in the absence of arabinose and that such levels were sufficient to satisfy the requirement of the cell for glutamate. The presence of arabinose in the medium, however, was required to complement the acetate phenotype of strain JE3884 (data not shown). This result was consistent with a requirement for higher levels of GltA when the cell was growing on acetate. The presence of arabinose in the medium also restored propionate toxicity in strain JE3777 (carries allele gltAGTG) and in the prpC- gltA- double mutant strain JE4556 carrying plasmid pGLTA2 (data not shown). It was concluded that high levels of citrate synthase were deleterious to a prpC mutant lacking 2-methylcitrate synthase activity when the cell was growing in medium containing propionate and succinate.

GltA Catalyzes the Synthesis of 2-Methylcitrate from Propionyl-CoA and Oxaloacetate-- All of the in vivo data strongly suggested that GltA activity was deleterious to cell growth, probably because this enzyme was synthesizing 2-methylcitrate from propionyl-CoA and oxaloacetate. To directly address this possibility, the gltA+ gene was overexpressed using plasmid pGLTA3. Homogeneous H6GltA protein was obtained using nickel affinity chromatography (Fig. 3). The H6GltA protein had a specific activity of 24 µmol of product/min/mg of protein, using acetyl-CoA as substrate in the dithiobis-(2-nitrobenzoic acid) assay (45). This assay, however, detected only a trace of 2-methylcitrate synthase activity when propionyl-CoA substituted for acetyl-CoA in the reaction mixture (data not shown). To increase the sensitivity of the assay, [C-2,14C]propionyl-CoA was synthesized (see "Experimental Procedures") and used to assess the 2-methylcitrate synthase activity of GltA. [C-2,14C]Propionyl-CoA was synthesized using the propionyl-CoA synthetase (PrpE) enzyme (47). The prpE+ gene was overexpressed with a C-terminal chitin-binding protein fusion using vector pTYB2 (New England Biolabs). Homogenous PrpE protein was obtained using a chitin affinity resin. An additional C-terminal glycine residue was added to PrpE to allow removal of the chitin-binding protein. Purified PrpE protein had a specific activity of 10 µmol of product/min/mg of protein, using propionate as substrate in a coupled assay (44). [C-2,14C]Propionate was completely converted to [C-2,14C]propionyl-CoA.


View larger version (93K):
[in this window]
[in a new window]
 
Fig. 3.   SDS-polyacrylamide gel electrophoresis of 2 µg of purified H6GltA and PrpE proteins with mid-range molecular mass standards. Lane SM, size markers; lane 1, H6GltA; lane 2, PrpE.

Homogeneous PrpC (2-methylcitrate synthase) enzyme was used as a positive control for the synthesis of [C-2,14C]2-methylcitrate from [C-2,14C]propionyl-CoA and oxaloacetate. Hydrochloric acid was added to reaction mixtures (final concentration, 1 N) containing GltA or PrpC to stop the reaction, and products and reactants in each reaction mixture were separated using thin layer chromatography (Fig. 4). Under the conditions used, [C-2,14C]2-methylcitrate displayed a relative mobility (Rf) of 0.63, as determined by the PrpC control reaction. In the GltA reaction, three 14C-labeled compounds were present on the TLC plate (Fig. 4). Control experiments with authentic standards established that the compound near the solvent front (Rf of 0.25) was [C-2,14C]propionate and that the compound at the origin was [C-2,14C]propionyl-CoA (data not shown). A 14C-labeled compound with the same Rf value as [C-2,14C]2-methylcitrate was evident in the GltA reaction (Fig. 4). The synthesis of this 14C-labeled compound by GltA was dependent on the addition of oxaloacetate to the reaction mixture, lending support to the conclusion that the labeled compound synthesized by GltA was 2-methylcitrate.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 4.   Synthesis of [14C]2-methylcitrate using pure PrpC and GltA. Reaction products were separated on silica TLC plates using a chloroform:methanol (3:2) solvent system. Lane 1 shows the PrpC reaction products, and lane 2 shows the GltA reaction products. Locations of [14C]propionate, [14C]propionyl-CoA, and [14C]2-methylcitrate are indicated.

2-Methylcitrate Synthase (PrpC) Can Substitute for GltA during Glutamate Biosynthesis-- The ability of PrpC to compensate for the lack of GltA in gltA mutants was assessed. Mutant strains lacking citrate synthase activity are glutamate auxotrophs when growing on glucose (52). Surprisingly, GltA activity was not required for growth on propionate as a carbon and energy source, suggesting that PrpC was able to synthesize citrate from acetyl-CoA and oxaloacetate (data not shown). This observation was supported by the plate phenotypes shown in Fig. 2. Taken together, these observations suggested that PrpC had sufficient citrate synthase activity to substitute for GltA during glutamate production in the cell. Consistent with this idea, plasmid pPRP35 (ParaBAD-prpC+; Table I) (54) complemented the glutamate auxotrophy of a gltA mutant on minimal medium supplemented with glucose even in the absence of arabinose in the medium (data not shown). This plasmid also complemented the acetate phenotype of gltA mutants, but the medium had to be supplemented with 1 mM arabinose (Fig. 5), indicating that a higher level of citrate synthase activity was needed during growth on acetate.


View larger version (20K):
[in this window]
[in a new window]
 
Fig. 5.   PrpC compensates for the lack of GltA in gltA mutants. Strains were grown in minimal medium supplemented with 50 mM acetate and ampicillin. The open squares show the growth of a gltA+ strain (JE4271); the solid circles show the growth of a gltA- strain (JE4274) with prpC+ provided in trans (pPRP35); the open circles represent the growth without arabinose; and the filled circles represent the growth with 1 mM arabinose.


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Insights into why propionate is toxic to cells were obtained through the genetic and biochemical analyses of mutants of S. enterica serovar Typhimurium LT2 lacking the 2-methylcitric acid cycle and citrate synthase.

2-Methylcitrate or a Derivative of It Is a Potent Inhibitor of Cell Growth-- The data lead to the conclusion that cells that catabolize propionate via the 2-methylcitric acid cycle are at risk because 2-methylcitrate, or a derivative of it, is a potent inhibitor of cell growth. In prpC mutants (which lack 2-methylcitrate synthase), the accumulation of 2-methylcitrate appears to be enhanced when the cell grows on carbon and energy sources that increase the intracellular level of oxaloacetate, such as succinate or malate. This is not surprising because oxaloacetate is the cosubstrate needed for the synthesis of 2-methylcitrate. Despite the lack of PrpC, cells growing on succinate and propionate still synthesize 2-methylcitrate. The data show that this compound is synthesized by the Krebs cycle enzyme citrate synthase (GltA). GltA catalyzes a reaction very similar to that of PrpC, except that it uses acetyl-CoA as a substrate instead of propionyl-CoA in the condensation with oxaloacetate that yields citrate. Eucaryotic citrate synthases are known to use propionyl-CoA as a substrate at 1-2% the rate of acetyl-CoA (55, 56). The E. coli GltA enzyme is even less efficient, using propionyl-CoA at less than 0.1% the rate of acetyl-CoA (20). Even though the citrate synthase of S. enterica is not very proficient at making 2-methylcitrate, it is clear that the low levels made by this enzyme are sufficient to arrest cell growth.

It is important to consider the stereochemistry of 2-methylcitrate when thinking about its cytotoxic effects. 2-Methylcitrate has two chiral carbons; thus there are four different stereoisomers of this compound. The stereochemistry of the 2-methylcitrate product synthesized by GltA has not been determined, and neither has the one for the product of the PrpC reaction. In Yarrowia lipolytica (formerly Candida or Saccharomycopis lipolytica), the stereochemistry of the 2-methylcitric acid cycle has been investigated by several groups (57-59). However, there is some debate on the exact stereochemistry of the 2-methylcitrate produced by the synthase in this organism (59). Regardless of whether the products of the GltA and PrpC reactions are stereochemically different, it is clear that both products exert strong negative effects on cell growth. One probable target for 2-methylcitrate inhibition is aconitase. Mammalian aconitase (unspecified source) is inhibited noncompetitively with one diastereoisomer pair of 2-methylcitrate (27). However, 2-methylcitrate does not inhibit beef heart aconitase (26). In this work, pure preparations of aconitase A and B were not inhibited by synthetic 2-methylcitrate. A better understanding of the effects of 2-methylcitrate or its derivative(s) requires the identification of the target(s) affected by this metabolite.

The results of studies on the negative effects of propionyl-CoA on cell function (19-21) could be explained as an accumulation of 2-methylcitrate, especially if the 2-methylcitric acid cycle were functional in the bacteria where propionyl-CoA was found to inhibit. In the absence of this pathway, however, it is possible that if the ratio of propionyl-CoA to other important acyl-CoA intermediates was increased too much, the cell may find itself with insufficient acetyl-CoA and succinyl-CoA levels to function properly. Experiments aimed at learning how 2-methylcitrate inhibits growth are in progress.

Is the Propionate Catabolic Pathway in S. enterica a Detoxification Pathway?-- The propionate catabolic pathway may have evolved to solve the problem of high levels of propionyl-CoA accumulating in the cell. Given the composition of the environments occupied by S. enterica, it is possible that this bacterium may be under constant pressure to maintain the level of propionyl-CoA low enough to avoid the negative effects caused by its accumulation. Propionyl-CoA levels may increase in response to factors such as (i) propionate in the environment (4, 5, 8, 9); (ii) breakdown of odd chain fatty acids (60); (iii) the anaerobic catabolism of threonine (61); or (iv) the catabolism of 1,2-propanediol, a product of rhamnose and fucose fermentations (48, 62). In this bacterium, the 2-methylcitric acid cycle may function as a detoxification pathway for propionyl-CoA. It appears that in wild-type S. enterica, the deleterious synthesis of 2-methylcitrate by GltA is avoided probably by the low Km of the PrpC enzyme for propionyl-CoA (48 µM) (23). During propionate breakdown, the level of 2-methylcitrate at any given point must be kept low by the enzymes acting downstream of 2-methylcitrate, i.e. PrpD and PrpB. The biochemical characterization of the PrpD and PrpB enzymes is needed to investigate this hypothesis.

    ACKNOWLEDGEMENTS

We thank J. Enos-Berlage and D. Downs for strains and DNA sequence information prior to publication.

    FOOTNOTES

* This work was supported in part by National Institutes of Health Grant GM62203 (to J. C. E.-S.)The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by a National Science Foundation predoctoral fellowship and by National Institutes of Health Biotechnology Training Grant GM08349.

§ To whom correspondence should be addressed: Dept. of Bacteriology, 1550 Linden Dr., Madison, WI 53706-1567. Tel.: 608-262-7379; Fax: 608-262-9865; E-mail: jcescala@facstaff.wisc.edu.

Published, JBC Papers in Press, March 16, 2001, DOI 10.1074/jbc.M100244200

2 A. R. Horswill and J. C. Escalante-Semerena, unpublished results.

    ABBREVIATIONS

The abbreviations used are: SCFA, short chain fatty acid; Ap, ampicillin; H6, hexahistidine tag; NB, nutrient broth; PCR, polymerase chain reaction; Tn10d(Tc), Tn10DEL16DEL17; Tc, tetracycline; MudJ, MudI1734; kb, kilobase(s)..

    REFERENCES .
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Macfarlane, G. T., and Macfarlane, S. (1997) Scand. J. Gastroenterol. Suppl. 222, 3-9
2. Cherrington, C. A., Hinton, M., Mead, G. C., and Chopra, I. (1991) Adv. Microb. Physiol. 32, 88-107
3. Kabara, J. J., and Eklund, T. (1991) in Food Preservatives (Russell, N. J. , and Gould, G. W., eds) , pp. 45-71, Glasgow Blachie, New York
4. Lück, E., and Jager, M. (1997) Antimicrobial Food Additives: Characteristics, Uses, and Effects , 2nd Ed. , pp. 145-151, Springer, New York
5. Cummings, J. H., Pomare, E. W., Branch, W. J., Naylor, C. P., and Macfarlane, G. T. (1987) Gut 28, 1221-1227[Abstract]
6. Hume, M. E., Corrier, D. E., Ambrus, S., Hinton, A., Jr., and DeLoach, J. R. (1993) Avian Dis. 37, 1051-1056[Medline] [Order article via Infotrieve]
7. Hinton, A., Jr., and Hume, M. E. (1996) J. Appl. Bacteriol. 81, 188-190[Medline] [Order article via Infotrieve]
8. Barnes, E. M., Impey, C. S., and Stevens, B. J. (1979) J. Hyg. 82, 263-283
9. Byrne, B. M., and Dankert, J. (1979) Infect. Immun. 23, 559-563[Medline] [Order article via Infotrieve]
10. Bohnhoff, M., and Miller, C. P. (1962) J. Infect. Dis. 111, 117-127[Medline] [Order article via Infotrieve]
11. Meynell, G. G., and Subbaiah, T. V. (1963) Br. J. Exp. Pathol. 44, 197-208[Medline] [Order article via Infotrieve]
12. Meynell, G. G. (1963) Br. J. Exp. Pathol. 44, 209-219
13. Matlho, G., Himathongkham, S., Riemann, H., and Kass, P. (1997) Avian Dis. 41, 58-61[Medline] [Order article via Infotrieve]
14. McHan, F., and Shotts, E. B. (1992) Avian Dis. 36, 139-142[Medline] [Order article via Infotrieve]
15. Thompson, J. L., and Hinton, M. (1997) Br. Poult. Sci. 38, 59-65[Medline] [Order article via Infotrieve]
16. Salmond, C. V., Kroll, R. G., and Booth, I. R. (1984) J. Gen. Microbiol. 130, 2845-2850[Medline] [Order article via Infotrieve]
17. Blankenhorn, D., Phillips, J., and Slonczewski, J. L. (1999) J. Bacteriol. 181, 2209-2216[Abstract/Free Full Text]
18. Russell, J. B. (1992) J. Appl. Bacteriol. 73, 363-370
19. Maruyama, K., and Kitamura, H. (1985) J. Biochem. (Tokyo) 98, 819-824[Abstract]
20. Man, W.-J., Li, Y., Connor, C. D., and Wilton, D. C. (1995) Biochim. Biophys. Acta 1250, 69-75[Medline] [Order article via Infotrieve]
21. Sealy-Lewis, H. M., and Fairhurst, V. (1998) Microbiology 144, 1895-1900[Abstract]
22. Brock, M., Fischer, R., Linder, D., and Buckel, W. (2000) Mol. Microbiol. 35, 961-973[CrossRef][Medline] [Order article via Infotrieve]
23. Horswill, A. R., and Escalante-Semerena, J. C. (1999) J. Bacteriol. 181, 5615-5623[Abstract/Free Full Text]
24. Textor, S., Wendisch, V. F., De Graaf, A. A., Müller, U., Linder, M. I., Linder, D., and Buckel, W. (1997) Arch. Microbiol. 168, 428-436[CrossRef][Medline] [Order article via Infotrieve]
25. Hammelman, T. A., O'Toole, G. A., Trzebiatowski, J. R., Tsang, A. W., Rank, D., and Escalante-Semerena, J. C. (1996) FEMS Microbiol. Lett. 137, 233-239[CrossRef][Medline] [Order article via Infotrieve]
26. Beach, R. L., Aogaichi, T., and Plaut, G. W. E. (1977) J. Biol. Chem. 252, 2702-2709[Abstract]
27. Cheema-Dhadli, S., Leznoff, C. C., and Halperin, M. L. (1975) Pediatr. Res. 9, 905-908[Abstract]
28. Davis, R. W., Botstein, D., and Roth, J. R. (1980) A Manual for Genetic Engineering: Advanced Bacterial Genetics , pp. 78-79, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
29. Berkowitz, D., Hushon, J. M., Whitfield, H. J., Roth, J., and Ames, B. N. (1968) J. Bacteriol. 96, 215-220[Medline] [Order article via Infotrieve]
30. Schmieger, H. (1971) Mol. Gen. Genet. 100, 378-381
31. Schmieger, H., and Bakhaus, H. (1973) Mol. Gen. Genet. 120, 181-190[Medline] [Order article via Infotrieve]
32. Chan, R. K., Botstein, D., Watanabe, T., and Ogata, Y. (1972) Virology 50, 883-898[Medline] [Order article via Infotrieve]
33. Seidman, C. G., Struhl, K., Sheen, J., and Jessen, T. (1997) in Current Protocols in Molecular Biology (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds) Vol. 1, units 1.8.-1.8.10, Wiley Interscience, New York
34. Tsai, S. P., Hartin, R. J., and Ryu, J. (1989) J. Gen. Microbiol. 135, 2561-2567[Medline] [Order article via Infotrieve]
35. Ryu, J.-I., and Hartin, R. J. (1990) BioTechniques 8, 43-45
36. Way, J. C., Davis, M. A., Morisato, D., Roberts, D. E., and Kleckner, N. (1984) Gene (Amst.) 32, 369-379[CrossRef][Medline] [Order article via Infotrieve]
37. O'Toole, G. A., and Kolter, R. (1998) Mol. Microbiol. 28, 449-461[CrossRef][Medline] [Order article via Infotrieve]
38. Parker, J. D., Rabinovitch, P. S., and Burmer, G. C. (1991) Nucleic Acids Res. 19, 3055-3060[Abstract]
39. Voytas, D. (2000) in Current Protocols in Molecular Biology (Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K., eds) Vol. 1, units 2.5A.1-2.5A.9, Greene Publishing Associates & Wiley Interscience, New York
40. Enos-Berlage, J. L., and Downs, D. M. (1997) J. Bacteriol. 179, 3989-3996[Abstract]
41. Guzman, L.-M., Belin, D., Carson, M. J., and Beckwith, J. (1995) J. Bacteriol. 177, 4121-4130[Abstract]
42. Hanahan, D. (1983) J. Mol. Biol. 166, 557-580[Medline] [Order article via Infotrieve]
43. Inoue, H., Nojima, H., and Okayama, H. (1990) Gene (Amst.) 96, 23-28[CrossRef][Medline] [Order article via Infotrieve]
44. Chang, K.-H., Liang, P.-H., Beck, W., Scholten, J. D., and Dunaway-Mariano, D. (1992) Biochemistry 31, 5605-5610[Medline] [Order article via Infotrieve]
45. Srere, P. A., Brazil, H., and Gonen, L. (1963) Acta Chem. Scand. 17, S129-S134
46. Dawson, R. M. C., Elliott, D. C., Elliott, W. H., and Jones, K. M. (1986) Data for Biochemical Research , 3rd Ed. , pp. 388-389, Oxford University Press, Oxford
47. Horswill, A. R., and Escalante-Semerena, J. C. (1999) Microbiology 145, 1381-1388[Abstract]
48. Obradors, N., Badia, J., Baldoma, L., and Aguilar, J. (1988) J. Bacteriol. 170, 2159-2162[Medline] [Order article via Infotrieve]
49. Bradford, M. M. (1976) Anal. Biochem. 72, 248-255[CrossRef][Medline] [Order article via Infotrieve]
50. Laemmli, U. K. (1970) Nature 227, 680-685[Medline] [Order article via Infotrieve]
51. Sasse, J. (1991) in Current Protocols in Molecular Biology (Ausubel, F. A. , Brent, R. , Kingston, R. E. , Moore, D. D. , Seidman, J. G. , Smith, J. A. , and Struhl, K., eds), Vol. 1 , pp. 10.6.1-10.6.8, Wiley Interscience, New York
52. Lakshmi, T. M., and Helling, R. B. (1976) J. Bacteriol. 127, 76-83[Medline] [Order article via Infotrieve]
53. Hartz, D., McPheeters, D. S., and Gold, L. (1991) J. Mol. Biol. 218, 83-97[Medline] [Order article via Infotrieve]
54. Horswill, A. R., and Escalante-Semerena, J. C. (1997) J. Bacteriol. 179, 928-940[Abstract]
55. Brandänge, S., Josephson, S., Måhlén, A., and Mörch, L. (1984) Acta Chem. Scand. 38, 695-700
56. Weidman, S. W., and Drysdale, G. R. (1979) Biochem. J. 177, 169-174[Medline] [Order article via Infotrieve]
57. Brandänge, S., Josephson, S., Mahlen, A., Morch, L., Sweetman, L., and Vallen, S. (1977) Acta Chem. Scand. 31, 628-630
58. Tabuchi, T., and Hara, S. (1974) Agr. Biol. Chem. 38, 1105-1106
59. van Rooyen, J. P., Mienie, L. J., Erasmus, E., De Wet, W. J., Ketting, D., Duran, M., and Wadman, S. K. (1994) J. Inherit. Metab. Dis. 17, 738-747[Medline] [Order article via Infotrieve]
60. Clark, D. P., and Cronan, J. E. (1996) in Escherichia coli and Salmonella: Cellular and Molecular Biology (Neidhardt, F. C. , Curtis, R., III , Ingraham, J. L. , Lin, E. C. C. , Low, K. B. , Magasanik, B. , Reznikoff, W. S. , Riley, M. , Schaechter, M. , and Umbarger, H. E., eds), Vol. 1 , pp. 343-357, American Society for Microbiology, Washington, D.C.
61. Hesslinger, C., Fairhurst, S. A., and Sawers, G. (1998) Mol. Microbiol. 27, 477-492[CrossRef][Medline] [Order article via Infotrieve]
62. Bobik, T. A., Havemann, G. D., Busch, R. J., Williams, D. S., and Aldrich, H. C. (1999) J. Bacteriol. 181, 5967-5975[Abstract/Free Full Text]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.